Advertisement

ADVERTISEMENT

chronic lymphocytic leukemia

News
Elevated Risk of Atrial Fibrillation or Stroke in Patients With CLL Receiving Ibrutinib Treatment Has Minimal Impact on TTNT and TTD
02/23/2023
A recent study evaluated the real-world persistence and time to next treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), including those at high risk for atrial fibrillation or stroke, who receive...
A recent study evaluated the real-world persistence and time to next treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), including those at high risk for atrial fibrillation or stroke, who receive...
A recent study evaluated the...
02/23/2023
Journal of Clinical Pathways
Real-World Ibrutinib Dose Reductions, Discontinuations in CLL
Videos
Real-World Ibrutinib Dose Reductions, Discontinuations in CLL
03/11/2021
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD,...
03/11/2021
Journal of Clinical Pathways
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
Videos
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
12/17/2020
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses...
12/17/2020
Journal of Clinical Pathways
News
Evaluating Neutropenia Prevalence After Venetoclax Therapy for CLL
06/23/2020
A study at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020) evaluated fixed duration venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)...
A study at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020) evaluated fixed duration venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)...
A...
06/23/2020
Journal of Clinical Pathways
News
Long-Term Follow-Up of BTK Inhibitor in Symptomatic Treatment-Naïve CLL
06/15/2020
Long-term data from ACE-CL-001 further supports the favorable results of acalabrutinib in phase III studies for patients with symptomatic, treatment-naïve chronic lymphocytic leukemia (CLL). Results of the study...
Long-term data from ACE-CL-001 further supports the favorable results of acalabrutinib in phase III studies for patients with symptomatic, treatment-naïve chronic lymphocytic leukemia (CLL). Results of the study...
...
06/15/2020
Journal of Clinical Pathways
News
BTK Inhibitor Effective in Patients With Progressive, High-Risk CLL
06/15/2020
Bruton tyrosine kinase (BTK) inhibitor therapy is effective in patients with chronic lymphocytic leukemia (CLL) who are resistant to prior venetoclax treatment, according to a new study presented at the European...
Bruton tyrosine kinase (BTK) inhibitor therapy is effective in patients with chronic lymphocytic leukemia (CLL) who are resistant to prior venetoclax treatment, according to a new study presented at the European...
Bruton...
06/15/2020
Journal of Clinical Pathways
News
Venetoclax-Based Time-Limited Therapy Well Tolerated, Effective in CLL
06/10/2020
Zanubrutinib plus venetoclax and obinutuzumab is well tolerated and achieves rapid undetectable minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL), according to a presentation at the...
Zanubrutinib plus venetoclax and obinutuzumab is well tolerated and achieves rapid undetectable minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL), according to a presentation at the...
...
06/10/2020
Journal of Clinical Pathways
News
Acalabrutinib Significantly Improves Survival in Relapsed, Refractory CLL
06/03/2020
Compared with two rituximab-containing regimens, acalabrutinib significantly improves progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL) and has a comparable safety profile to these...
Compared with two rituximab-containing regimens, acalabrutinib significantly improves progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL) and has a comparable safety profile to these...
...
06/03/2020
Journal of Clinical Pathways
News
Long-Term Outcomes of High-Dose CAR-T Therapy for Relapsed, Refractory CLL
05/12/2020
Chimeric antigen receptor T-cell targeting CD-19 (CAR T-19) may be more effective at a higher dose (5 x 108) than a standard lower dose (5 x 107) in patients with relapsed or refractory chronic lymphocytic leukemia...
Chimeric antigen receptor T-cell targeting CD-19 (CAR T-19) may be more effective at a higher dose (5 x 108) than a standard lower dose (5 x 107) in patients with relapsed or refractory chronic lymphocytic leukemia...
...
05/12/2020
Journal of Clinical Pathways
The Challenge of Developing Pathways in a Rapidly Evolving Clinical Space: Chronic Lymphocytic Leukemia as a Case Study
Perspectives
The Challenge of Developing Pathways in a Rapidly Evolving Clinical Space: Chronic Lymphocytic Leukemia as a Case Study
03/16/2020
Abstract: Clinical pathways represent an effort to optimize value-based clinical decision making by standardizing (when appropriate) evidence-based care to offer patients the best outcome while remaining mindful of...
Abstract: Clinical pathways represent an effort to optimize value-based clinical decision making by standardizing (when appropriate) evidence-based care to offer patients the best outcome while remaining mindful of...
...
03/16/2020
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 6 ⁠–⁠ November 8
NEI Congress
November 7 ⁠–⁠ November 10
ECS
November 8 ⁠–⁠ November 10
WoundCon
November 8
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use